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USPIO-Enhanced Magnetic Resonance Imaging for
Nodal Staging in Patients With Head and Neck
Cancer
Luı´s Curvo-Semedo, MD,1 Mo´nica Diniz, MD,1 Jorge Migue´is, MD,2
Maria-Jose´ Julia˜o, MD,3 Paula Martins, RT,1 Alda Pinto, RT,1
and Filipe Caseiro-Alves, MD, PhD1*
Purpose: To determine the accuracy of ultrasmall super-
paramagnetic iron oxide (USPIO)-enhanced magnetic res-
onance imaging (MRI) for nodal staging in patients with
head and neck cancer.
Materials and Methods: Twenty patients with carcinomas
of the upper aerodigestive tract were prospectively enrolled.
MRI was performed before and 24–36 hours after intrave-
nous infusion of an USPIO agent, ferumoxtran-10 (Sine-
rem; Guerbet, France; and Combidex; AdvancedMagnetics)
at a dose of 2.6 mg Fe/kg using T2-weighted spin-echo and
gradient-echo sequences. Surgery was performed the same
day or the day after the ferumoxtran-10–enhanced MR
examination. Based on MRI, selected nodes were surgically
removed and directly correlated with pathology using he-
matoxylin-eosin (H&E) and Perls stainings.
Results: A total of 63 nodes were studied; 36 were non-
metastatic, 25 metastatic, and two inﬂammatory. Feru-
moxtran-10–enhanced MRI allowed diagnosis of 24 meta-
static and 30 nonmetastatic nodes, yielding a sensitivity of
96%, a speciﬁcity of 78.9%, a positive predictive value of
75%, and a negative predictive value of 96.8%, compared to
64%, 78.9%, 66.6%, and 76.9%, respectively, for nonen-
hanced MRI. Accuracy of ferumoxtran-10–enhanced MRI
was 85.7%. The gradient-echo T2-weighted sequence was
the most accurate to detect signal loss in nonmetastatic
nodes.
Conclusion: USPIO-enhanced MRI is useful for nodal stag-
ing of patients with head and neck cancers.
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CROSS-SECTIONAL IMAGING plays an important role
in the study of patients with head and neck squamous
cell carcinomas, allowing detection of lymph nodes (LN)
missed by physical examination, or demonstrating in-
vasion of structures such as the skull base or the ca-
rotid arteries (1,2). Using these imaging modalities, the
criteria for diagnosing metastatic nodes is mainly di-
mensional. Measurements include the minimum trans-
axial diameter, the maximum transaxial diameter or a
ratio between the maximum longitudinal and the max-
imum axial diameters (3–7). Other parameters, such as
morphological criteria or the pattern of enhancement,
are regarded as less important in this setting. Nodal
metastases in the head and neck are frequently smaller
than 10 mm, sometimes even under 5 mm in diameter,
a fact that accounts for the unsatisfactory performance
of the current imaging techniques (8,9).
MRI can be improved when using contrast agents
suited for intravenous MR lymphography, such as the
new ultrasmall superparamagnetic iron oxide (USPIO)
particles, which are taken up by cells of the reticuloen-
dothelial system of nonmetastatic LN (10–15). As it has
been shown in previous studies, iron oxide deposition
leads to a decrease in the signal intensity (SI) in non-
metastatic nodes due to the T2 shortening effects,
whereas metastatic nodes, devoid of macrophages, will
not undergo SI changes when using T2-weighted se-
quences (11). The clinical use of this contrast agent is
still under evaluation on phase III clinical trials (15–20).
Reports show promising results, with sensitivity and
speciﬁcity values ranging from 59% to 100% and 77%
to 100%, respectively (9,10,16,17,19,20).
The purpose of this study was to perform a direct
comparison between MRI and pathological examination
of selected LN in patients with head and neck cancer,
determining the enhancement patterns of metastatic
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and nonmetastatic nodes, and evaluating the diagnos-
tic value of ferumoxtran-10–enhanced MRI in this
group of patients. The diagnostic performance of differ-
ent pulse sequences was also additionally assessed.
MATERIALS AND METHODS
Patients
This is a single-institutional study that is part of a
multicentric phase III-B clinical trial, partially sup-
ported by Guerbet (Aulnay-sous-Bois, France). The eth-
ical committee at our institution approved the study
protocol, and informed written consent was obtained
from all the patients enrolled. Inclusion criteria were as
follows: patients of either sex, 18 years old or older
(postmenopausal women or female patients with effec-
tive contraception), patients with histologically proven
head and neck squamous cell carcinomas of the upper
aerodigestive tract (regardless of clinical TNM stage)
without previous treatment by chemotherapy and/or
radiotherapy and patients scheduled to undergo sur-
gery with bilateral lymphadenectomy within 15 days of
contrast-enhanced MRI. Exclusion criteria were as fol-
lows: patients with contraindications to MRI, patients
with a history of allergy to dextran or drugs contain-
ing iron salts, patients with a low-reserve hemody-
namic status susceptible to decompensation after ad-
ministration of contrast agent, patients who received
gadolinium complexes within two days or iron oxide
nanoparticles within seven days before MRI, patients
who underwent previous treatment by chemotherapy
and/or radiotherapy before surgery, breastfeeding fe-
male patients, patients already included in another
clinical trial, patients under guardianship, and unco-
operative patients.
Twenty patients were consecutively enrolled in the
study, from February 2001 to October 2002. All pa-
tients were male and had a mean age of 57.3 years, with
ages ranging from 39 to 78 years old. Primary tumors
were located at the following regions: hypopharynx (N
10); larynx (N  8); and oropharynx (N  2). The initial
clinical TNM Classiﬁcation of Malignant Tumours
(TNM) staging based on the International Union Against
Cancer (UICC) staging system classiﬁed one patient as
T1, two patients as T2, 11 patients as T3, and six pa-
tients as T4. Seven patients were staged as N0, two
patients as N1, 10 patients as N2, and one patient as
N3.
Contrast Agent
The contrast agent ferumoxtran-10 (Sinerem, Guerbet,
France; Combidex, Advanced Magnetics, USA) consists
of lyophilized ultrasmall iron oxide particles (5 nm in
diameter) covered with low-molecular-weight dextran.
Each particle has a total diameter of approximately 30
nm. The contrast agent was reconstituted using 10 mL
of a 0.9% saline solution. The administered dose was
2.6 mg of iron per kilogram of body weight. The corre-
sponding volume of the contrast agent solution was
diluted in 100 mL of a 0.9% saline solution. This ﬁnal
volume was injected intravenously, by drip infusion
through a ﬁlter (pore size: 0.22 m) at a rate of 4 mL/
minute, with an average infusion time of approximately
30 minutes. Patients were kept under medical survey
during the administration of the contrast agent and for
at least two hours after completion of the infusion.
MR Imaging
All studies were performed in a 1.5-T MR magnet (Mag-
netom 63 SP; Siemens, Erlangen, Germany), using the
Helmholtz neck coil. Images were obtained with a spin-
echo (SE) proton density (PD)/T2-weighted sequence
(TR: 1995 msec; TE: 25/90 msec; two acquisitions) and
a gradient-echo (GRE) T2-weighted sequence (TR: 750
msec; TE: 15 msec; ﬂip angle: 30°; two acquisitions).
Both sequences were obtained in the paraaxial plane,
parallel to the glottic level. Parallel presaturation bands
and ﬂow compensation pulses were routinely applied.
Fifteen slices were acquired for each sequence, with a
section thickness of 5 mm and an intersection gap of
0.5 mm. The ﬁeld of view (FOV) was 200  200 mm and
the matrix size was 192 (phase-encoding direction) 
256 (frequency-encoding direction) pixels, determining
an in-plane pixel size of 1.04  0.78mm. Examinations
were performed before and after intravenous adminis-
tration of ferumoxtran-10. The nonenhanced examina-
tion was acquired three days before the postcontrast
study. This latter examination was obtained 24 to 36
hours after the end of the ferumoxtran-10 infusion us-
ing the same imaging parameters of the nonenhanced
study.
Surgical Mapping and Pathologic Correlation
Lymph nodes were selected before surgery, both by the
radiologist and the surgeon, based on MRI examina-
tions. During neck dissection, MR images were avail-
able in the surgical suite in order to properly identify
the selected nodes which were removed and separately
sent for pathologic examination. This analysis included
measurement of the nodal diameters, followed by mul-
tiple sections of the node, with macroscopic examina-
tion of the section planes. Lymph nodes or nodal sec-
tions were included in parafﬁn, after ﬁxation in a
tamponated formalin solution for at least 24 hours.
Sections with a thickness of 4 m were obtained for
each node or section; initially, two histology glasses
from each section (or from the whole LN), were studied
with standard hematoxylin and eosin (H&E) and Perls
stains. The pathologist reported the nodal status on
H&E stain (normal, inﬂammatory, or metastatic—to-
tally or partially), the status on Perls stain (iron depo-
sition absent or present—mild, moderate, or marked)
and any important and/or uncommon histopathologic
feature found. In doubtful cases, additional sections
were obtained and examined. Despite the study of all
LN surgically removed only those that were correlated
with MRI were included for the purpose of this study.
One patient, although submitted to the post-feru-
moxtran-10 examination, was excluded from the imag-
ing and pathologic analysis, because ferumoxtran-10
infusion was prematurely stopped and not resumed,
due to the appearance of facial redness, mild dyspnea,
and moderate hypotension (80/50 mmHg), that disap-
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peared promptly after intravenous administration of
methylprednisolone and saline solution. This patient
received only 25% of the calculated ferumoxtran-10
dose. As a result, the efﬁcacy was assessed on 19 pa-
tients, for a total of 63 LN being evaluated. All patients
were submitted to tumor resection with bilateral radical
neck dissection, with 13 having surgery the same day of
the ferumoxtran-10–enhanced MR study and six one
day after.
Image and Data Analysis
The MRI studies were prospectively interpreted by two
radiologists (who routinely perform head and neck MR
examinations), and reading results for each sequence
were obtained by consensus.
The following characteristics were assessed for each
selected LN: short-axis diameter (on nonenhanced MRI
nodes were considered metastatic if their short axis
diameter was at least equal to 10 mm), location (side
and neck group, according to the nomenclature of the
American Academy of Otolaryngology–Head and Neck
Surgery’s Committee for Head and Neck Surgery and
Oncology (21)) and structure (homogeneous or hetero-
geneous).
On the ferumoxtran-10–enhanced examination a vi-
sual comparison of the nodal signal intensity changes
was performed as three different readings (Fig. 1): in
reading 1 (comparison of SI loss between ferumoxtran-
10–enhanced SE PD and T2-weighted sequences), all
LN that showed a SI decrease from PD to T2-weighted
images were considered nonmetastatic. Nodes display-
ing no SI decrease, areas of high SI or a hyperintense
peripheral rim on post-ferumoxtran-10 T2-weighted
images in comparison to PD-weighted images were
considered metastatic. In reading 2 (comparison of
pre- and post-ferumoxtran-10 GRE T2-weighted se-
quences), nodes showing a homogeneous SI decrease in
ferumoxtran-10–enhanced images in comparison to
nonenhanced images or being hypointense with small
and punctate hyperintense foci, were interpreted as
nonmetastatic. Lymph nodes showing no SI loss com-
pared to nonenhanced examination, containing foci of
high SI or a hyperintense peripheral rim were consid-
ered metastatic. In reading 3 (comparison of ferumoxt-
ran-10-enhanced GRE T2-weighted sequence to SI of
paravertebral muscle), nodes were considered non-
metastatic if they appeared hypointense (or hypoin-
tense with punctate and scarce hyperintense foci) to
paravertebral muscle. Nodes remaining iso- or hyper-
intense after ferumoxtran-10 administration and that
showed a hyperintense peripheral rim or extensive ar-
eas of high SI were considered metastatic.
Statistical analysis was performed determining the
values of sensitivity, speciﬁcity, positive predictive
value, negative predictive value, and accuracy of non-
enhanced and ferumoxtran-10–enhanced MRI. Accu-
racy between readings were analyzed using the chi
squared test, with P values considered signiﬁcant if
0.05.
RESULTS
Intravenous infusion of ferumoxtran-10 was well toler-
ated and without major side effects in 17 patients. One
patient experienced mild sweating, which disappeared
after few minutes without any treatment or change in
the infusion protocol. In another patient, the contrast
administration was momentarily interrupted due to
mild hypotension that spontaneously and rapidly re-
covered; infusion was then carried on at a slower rate,
without any further complications. In one case, the
infusion was prematurely stopped and not resumed,
due to the appearance of facial redness, mild dyspnea,
and moderate hypotension, which subsided about 30
minutes after intravenous administration of methyl-
prednisolone (1 g) and 0.9% saline solution. This pa-
tient was excluded from the efﬁcacy analysis.
From the pathological study of the 19 patients sub-
mitted to cervical dissection, 821 LN were retrieved.
From these 44 were metastatic (5%) and 777 were non-
metastatic (95%). From the total pool of LN, individual
correlation between MRI and pathology was performed
for a total of 63 nodes (average: 3.3 nodes per patient;
range: 1–7 LN). Pathologic examination classiﬁed 36
(57%) as normal, 25 (40%) as metastatic (21 massively,
four partially) and two (3%) as inﬂammatory. The nodal
distribution by side, size, histologic result, and location
are summarized in Tables 1 and 2.
Regarding the nodes that were subject to imaging-
pathological correlation, nonmetastatic nodes had a
mean short axis of 7.8 mm (range: 4–15 mm); 8 LN had
a short axis equal to or larger than 10 mm. Metastatic
nodes had a mean short axis length of 15.1 mm, rang-
ing from 7 to 35 mm, with nine measuring less than 10
mm (Fig. 2).
On Perls stain, 26 normal nodes showed moderate or
marked deposition of iron. In eight normal LN, there
were only mild iron deposits and in another two iron
was not detected. Both inﬂammatory nodes revealed
Figure 1. Drawing for visual assessment of LN SI before and
after ferumoxtran-10 administration, establishing enhance-
ment criteria used to differentiate benign from metastatic
nodes. The PD-weighted images, insensitive to iron deposition,
were compared to the iron-sensitive sequence (T2-weighted).
LN showing a homogeneous SI decrease (I) on ferumoxtran-
10–enhanced T2-weighted images or minute hyperintense foci
(II) were considered nonmetastatic. Nodes that did not show SI
decrease (III), that contained obvious foci of high SI (IV) or a
hyperintense peripheral rim (V), or were heterogeneous (VI) on
T2-weighted images in comparison to PD-weighted images
were considered metastatic. The same features are applied to
the evaluation of GRE T2-weighted sequences. (PD, proton
density; T2-w, T2-weighted)
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mild iron deposition. Metastatic LN had scarce foci of
iron or no iron deposits in seven and 15 cases, respec-
tively. Two nodes showed moderate iron deposition and
massive deposits were present in only one case.
In nonenhanced MRI, there were 16 true-positive and
30 true-negative LN. There were eight false-positives
due to nonmetastatic nodes measuring 10 mm and
nine false-negatives due to LN with a short axis 10
mm. Nonenhanced MRI showed a sensitivity of 64%, a
speciﬁcity of 78.9%, a positive predictive value of
66.6%, and a negative predictive value of 76.9%, with
an accuracy of 73%.
Regarding the results for ferumoxtran-10–enhanced
MRI, in reading 1 (comparison of SI loss between SE PD
and T2-weighted sequences) all 25 metastatic LN and
21 true-negative cases were identiﬁed due to absence or
presence of SI loss on T2-weighted images, respectively.
Seventeen LN were false positive due to the absence of a
deﬁnite SI loss as reported by readers (Fig. 3). There
were no false negatives; this analysis showed a high
sensitivity (100%) but a low speciﬁcity (55.3%). The
positive predictive value, negative predictive value, and
accuracy values were 59.6%, 100% and 73%, respec-
tively. Although ferumoxtran-10–enhanced SE PD/T2-
weighted sequence was signiﬁcantly more sensitive
than nonenhanced MRI (P  0.0005), nonenhanced
MRI had a signiﬁcantly better speciﬁcity (P  0.0089).
Readings 2 and 3 (comparison of pre- and post-feru-
moxtran-10 GRE T2-weighted sequences and compar-
ison of ferumoxtran-10–enhanced GRE T2-weighted
sequence to SI of paravertebral muscle respectively)
provided similar results yielding 24 true positive nodes
(Fig. 4). Thirty nonmetastatic LN appeared homoge-
neously hypointense after ferumoxtran-10 enhance-
ment (reading 2) or were hypointense when compared
to SI of muscle (reading 3) (Fig. 3). Eight false positives
were seen due to the presence of a hyperintense periph-
eral rim (N  4) (Fig. 5) or heterogeneous SI loss com-
pared to nonenhanced images or muscle (N 4) (Fig. 6).
Finally, one metastatic LN displaying a homogeneous SI
decrease on post-ferumoxtran-10 GRE T2-weighted im-
ages was proved to be metastatic and thus yielded a
false negative result (Fig. 7). Readings 2 and 3 provided
a high sensitivity (96%) and a speciﬁcity of 78.9%. The
positive predictive value was 75% and the negative pre-
dictive value was 96.8%. The diagnostic accuracy was
the highest among all MRI studies (85.7%). The differ-
ence in sensitivity between nonenhanced MRI and feru-
moxtran-10–enhanced GRE T2-weighted studies was
highly signiﬁcant (P  0.0005), whereas speciﬁcity val-
ues were equivalent (78.9%; P  0.8341). Speciﬁcity of
readings 2 and 3 was signiﬁcantly better than that of
reading 1 (P  0.0089), for similar sensitivity values
(P 0.3378). Comparison between sensitivity and spec-
iﬁcity values regarding nonenhanced MRI and the var-
ious ferumoxtran-10–enhanced sequences are de-
picted in Table 3.
On a patient-by-patient analysis, nonenhanced MRI
recognized 12 true-positive patients and two true-neg-
ative patients, but erroneously classiﬁed three patients
as false-positive and two as false-negative. On ferumox-
tran-10–enhanced MRI all 14 metastatic patients were
correctly assigned as such, but reading 1 was respon-
sible for three false-positive results and readings 2 and
3 for two false-positives each. After ferumoxtran-10 ad-
ministration there were no false-negative patients.
Comparison between nonenhanced and ferumoxtran-
10–enhanced MRI is showed in Table 4.
Similarly to the node-by-node analysis, ferumoxtran-
10–enhanced studies improved the sensitivity and
speciﬁcity regarding the nonenhanced images, identify-
ing patients harboring metastasis with high sensitivity
(100%) with the GRE T2-weighted performing better
than the SE PD/T2-weighted sequence. Concerning pa-
tient management, it should be emphasized that in two
patients, only the ferumoxtran-10–enhanced studies
correctly assigned the presence of metastases on sub-
centimeter nodes.
DISCUSSION
Detection of metastatic LN in patients with head and
neck cancer is extremely relevant because it is one of
the most important factors inﬂuencing the prognosis;
the presence of nodal metastases reduces the ﬁve-year
survival to 50% regardless of the location or size of the
primary tumor (17,22). Cervical palpation is inaccurate
for staging purposes, since over 15% of patients clini-
cally staged as N0 may possess nodal metastases and
Table 2




I II III IV
Normal 1 24 11 0
Metastatic 1 7 14 3
Inﬂammatory 0 1 1 0
Table 1






Normal 4–15 7.8 24L/12R
Metastatic 7–35 15.1 11L/14R
Inﬂammatory 5–9 7 2L/0R
L  left, R  right.
Figure 2. Distribution of benign and metastatic LN according
to size (short-axis diameter). Nonmetastatic nodes tended to be
smaller, whereas metastatic nodes were more variable in size.
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rates of false-positive and false-negative cases can be as
high as 15% to 25% and 30% to 50%, respectively
(23,24). Due to this inaccuracy, most surgeons prefer to
overtreat patients, performing bilateral radical neck
dissections that may result in increased morbidity (9).
Accurate presurgical imaging studies are thus needed,
in an attempt to select the most appropriate surgical
procedure (23). Cross-sectional imaging has been
widely used in this setting and criteria for diagnosing
metastatic LN include the analysis of nodal structure,
clustering, shape, signs of extracapsular spread, and
size (5,22,25).
MRI, with its intrinsic high soft-tissue discrimina-
tion, was thought to be a superior technique for nodal
imaging, but the SI or the T2 relaxation times of meta-
static nodes do not differ or even overlap those obtained
in normal LN (26). Some studies did not show a clear
advantage of MRI over contrast-enhanced computed
tomography (CT) (27). To overcome these limitations,
the use of MRI enhanced with ultrasmall iron-based
contrast agents has been proposed (9–19). USPIO par-
ticles have been developed with the knowledge that they
are selectively taken by cells of the reticuloendothelial
system present in nonmetastatic LN, with differences in
enhancement reﬂecting the functional status of the
nodes, allowing discrimination of benign from malig-
nant ones (17,28). Although their use for human stud-
ies has been limited (9,10,15–20), they have showed
encouraging results, with reported high sensitivity and
speciﬁcity values (9,10,16,17,19,20). Recently, com-
bined positron emission tomography (PET)/CT has
been used successfully for staging of nodal disease in
Figure 3. Normal LN. From SE PD-weighted (a) to SE T2-weighted images (b), the selected node did not reveal a clear SI loss, and
thus was interpreted as metastatic. However, on the GRE T2-weighted sequence, the LN showed a clear homogeneous SI
decrease from nonenhanced (c) to ferumoxtran-10–enhanced (d) images, where it appears hypointense to skeletal muscle,
allowing its assignment as nonmetastatic.
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the neck, allowing simultaneous registration of ana-
tomic and metabolic datasets. PET/CT helps to over-
come the lack of anatomical detail of isolated PET stud-
ies and may provide useful functional information for
the discrimination of metastatic from nonmetastatic LN
(29). To the best of our knowledge, however, at present
there are no comparative studies with USPIO-enhanced
MRI regarding LN status on cervical cancers.
The results of our study conﬁrmed that using an
USPIO-enhanced MRI approach it is possible to differ-
entiate metastatic from nonmetastatic LN with a high
level of accuracy, based on functional criteria and not
solely on dimensional analysis. The data provided by
this study reinforces those from previous works in pa-
tients with head and neck cancers, which showed a
USPIO-enhanced MRI sensitivity of 95% to 96% and a
speciﬁcity of 78.9% to 84% (17). More recently, Sigal et
al (9), in a larger but distinct study using ferumoxt-
ran-10 and enrolling 90 patients, reported sensitivities
greater than 88% and speciﬁcities above 77%, in indi-
vidual nodal analysis.
We have found a signiﬁcant difference in the diagnos-
tic performance of ferumoxtran-10–enhanced se-
quences, when comparing the SE PD/T2-weighted se-
quences and GRE T2-weighted sequences, with the
latter performing better. Although the ferumoxtran-10–
enhanced SE PD/T2-weighted sequences allowed de-
tection of all metastatic nodes, they were not able to
demonstrate an unequivocal SI loss in a great propor-
tion of nonmetastatic LN, resulting in a low speciﬁcity
(55.3%). On the contrary, GRE T2-weighted images al-
lowed easier detection of nonmetastatic LN due to a
more pronounced SI loss after the administration of
ferumoxtran-10, providing the best contrast between
areas of nonenhancement and areas of intranodal iron
deposits (10,17). This is related to magnetic suscepti-
Figure 4. Metastatic LN, ferumoxtran-10–enhanced GRE T2-weighted sequence. a: The selected node remained hyperintense.
b: The correlated LN showed a peripheral hypointense area and a eccentrically-located hyperintense zone (bottom right, detail);
this latter area was interpreted as a partial metastasis and the pathological examination conﬁrmed the diagnosis (H&E, 200)
(c).
Figure 5. Normal LNmeasuring 6mm of short-axis corresponding to a false-positive ﬁnding on ferumoxtran-10–enhanced GRE
T2-weighted sequences. a: On the nonenhanced study the node is hyperintense. b: After ferumoxtran-10 administration there
is a peripheral hyperintense rim that was thought to represent metastatic inﬁltration. Pathological examination found a normal
histology only with a mild capsular thickening but without signs of neoplastic inﬁltration.
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bility effects caused by the intranodal iron when using
these sequences, which are deprived of the refocusing
180° pulse allowing for a greater T2-decay of tissues
containing the iron oxide particles. Since the results
obtained on the pre-/post-ferumoxtran-10 GRE T2-
weighted sequences were identical to the analysis of the
ferumoxtran-10–enhanced GRE T2-weighted sequence
compared to a standard nonenhancing tissue (muscle)
it seems reasonable to conclude that postcontrast im-
ages alone can be used to judge the nodal signal inten-
sity. However, we do not provide any evidence that
these results can be reproduced if reading is performed
by inexperienced readers or if applied to a subset of
small subcentimeter nodes. We found on ferumoxtran-
10–enhanced GRE T2-weighted images eight false-pos-
itives in small nodes 10 mm of small axis. Four LN
displayed a hyperintense peripheral rim with a central,
markedly hypointense area. Pathologic examination did
not reveal any particular feature except for a discrete
capsular thickening but devoid of metastasis. This sug-
gests that this pattern of nodal enhancement should
also be viewed as a pattern variant for normal enhance-
ment and not as a sign of metastatic involvement, as it
was previously pointed out by Rockall et al (30) when
evaluating pelvic lymph nodes in patients with gyneco-
logical cancers. Inﬂammatory nodes can also show a
reduced uptake of USPIO due to hyperplasia of the
germinal centers and paucity in macrophages as oc-
curred in one of our cases. In the study by Sigal et al (9)
false-positives resulted from inﬂammatory changes in
the center of the nodes (hyperplastic germinal centers),
with ferumoxtran-10 uptake by the macrophages only
at the periphery of the LN. The same problem has also
been reported in PET/CT studies, since inﬂammatory
Figure 6. Nonmetastatic LN causing two cases of false-positive results using GRE T2-weighted sequences. a: On the nonen-
hanced study, the selected nodes are hyperintense. b: After ferumoxtran-10 enhancement, the node on the right cervical chain
shows a slight heterogeneous decrease in SI (arrows). The LN on the left cervical chain also retains some hyperintense foci
(arrowheads). Both were devoid of metastases on pathological examination and corresponded to inﬂammatory LN containing
scarce focal iron deposits.
Figure 7. False-negative case after ferumoxtran-10 administration on GRE T2-weighted sequence. a: On the nonenhanced
study, this 7-mm node was homogeneously hyperintense. b: After ferumoxtran-10 administration, the LN became homoge-
neously hypointense. c: Pathology was positive for metastatic involvement but marked iron deposits were also identiﬁed (Perls,
200).
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changes also demonstrate an increased glucose metab-
olism, leading to false positive results (31). Other
causes of false-positive nodes are possible and have
been previously described, such as those related to the
administration of lower doses of USPIO agents (17), the
presence of necrosis or fatty metaplasia, a feature that
can be found in about 5% of nodes (28,32). The remain-
ing cases of false-positive results were due to a hetero-
geneous pattern of nodal enhancement rendering ex-
clusion of metastasis difﬁcult based solely on the visual
appreciation of SI.
The false-negative result reported on GRE images
corresponded to a 7-mm node, showing massive meta-
static deposits on pathologic examination, in which the
Perls stain revealed marked iron deposition. This LN did
not show, however, a substantial SI loss on the SE
PD/T2-weighted images and thus was correctly as-
signed asmetastatic in reading 1. Possible explanations
for this discrepancy may be related to the relatively
thick slices that were obtained, and to the “blooming
effect” (12,25) consisting of a strong magnetic suscep-
tibility artifact on GRE T2-weighted sequences, obscur-
ing nodal structure. Other false-negatives that had
been described were related to the presence of micro-
metastases (9). The issue of intranodal micrometasta-
ses can, in fact, remain a problem since they can be
present in as much as 10% of all tumor-positive spec-
imens, with 25% of positive neck dissections containing
metastases too small to be detected with the currently
available imaging techniques (33). Several causes for
false-negative results have also been described with
PET/CT, such as a small tumor burden in metastatic
nodes, nodal necrosis with a small rim of viable tumor
tissue, low tracer uptake in the LN, and imaging arti-
facts. Nodal metastases in close vicinity to the primary
tumor may also not be detectable as separate hyper-
metabolic foci if the latter shows very intense tracer
uptake (34).
It should be stressed that in our results, all false-
positives and false-negatives were seen in small nodes
10 mm. We think that this problem may have been
ampliﬁed in our study since a high-resolution tech-
nique using phased-array coils and/or three-dimen-
sional techniques was not available at that time in our
institution. This is especially true for the GRE T2-
weighted sequences, which are more prone to suffer
from magnetic susceptibility artifacts and possess
lower spatial resolution (35).
Our study has other limitations: the selection of the
LN to be correlated was based solely in the MR image
confrontation. The measurement of the nodal small
axis, even if performed on iron-insensitive images, con-
tains a certain degree of error, which may affect pre-
dominantly the precontrast study, since the criteria to
declare a LN as benign or malignant are mostly dimen-
sional. The visual analysis of the nodal SI changes,
which constitutes the main judgement criterion for
ferumoxtran-10–enhanced MRI, is also subjective and
prone to individual variability. In our study a side-by-
side or level-by-level evaluation was not performed and
only the correlated resected nodes were included. We
are aware that this approach carries a bias towards the
selection of larger LN, possibly causing an artiﬁcial in-
crease of sensitivity values for ferumoxtran-10–en-
hanced MRI because noncorrelated small metastatic
nodes may be disregarded. However, since 43 (68%) of
the LN selected for correlation were 10 mm in the
short-axis (Fig. 2), the potential effects of this selection
bias might have been minimized. Two patients (10.5%)
received a clear beneﬁt from ferumoxtran-10–en-
hanced MRI since only this technique was able to depict
metastatic nodal involvement. Since all patients har-
boring metastatic LN at all levels were correctly identi-
ﬁed on the ferumoxtran-10–enhanced study, the sur-
gical decision would not been adversely affected even if
we take in account the metastatic nodes that were not
subjected to direct radiologic-pathological confronta-
tion. It should be stressed that, from a clinical perspec-
tive, it is more relevant to rule out metastatic disease in
a given nodal level than to determine the exact number
of individual metastatic LN contained in it.
Table 3





SE PD/T2-w GRE T2-w pre/post GRE T2-w LN/muscle
Sensitivity 64% (16/25) 100% (25/25) 96% (24/25) 96% (24/25)
Speciﬁcity 78.9% (30/38) 55.3% (21/38) 78.9% (30/38) 78.9% (30/38)
SE  spin-echo, PD  proton density, T2-w  T2-weighted, GRE  gradient-echo.
Table 4





SE PD/T2-w GRE T2-w pre/post GRE T2-w LN/muscle
Sensitivity 85.7% (12/14) 100% (14/14) 100% (14/14) 100% (14/14)
Speciﬁcity 40% (2/5) 40% (2/5) 60% (3/5) 60% (3/5)
Accuracy 73.7% (14/19) 84.2% (16/19) 89.5% (17/19) 89.5% (17/19)
SE  spin-echo, PD  proton density, T2-w  T2-weighted, GRE  gradient-echo.
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In conclusion, ferumoxtran-10–enhanced MRI im-
proves the presurgical nodal staging of patients with
head and neck cancer. The different patterns of nodal
uptake in ferumoxtran-10–enhanced images must be
recognized in order to avoid false results. Due to its
exquisite sensitivity for the demonstration of intranodal
iron deposition, GRE T2-weighted sequence should be
preferred and systematically included in the imaging
protocol. A single postcontrast examination may be suf-
ﬁcient to judge the signal intensity modiﬁcation of
lymph nodes if compared to an internal reference such
as the nonenhancing muscular tissue.
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